Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavrostobart (PT199) in Advanced Solid Tumors, NSCLC, and PDAC (MORNINGSTAR)
NCT05431270Phase 2Recruiting
- Sponsor
- Phanes Therapeutics, Inc.
- Start
- Aug 2022
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mavrostobart in solid tumor, non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) (4 arms), sponsored by Phanes Therapeutics, Inc. Primary endpoints: Maximum Tolerated Dose at 90 days, Recommended Phase 2 Dose at 90 days and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
mavrostobart
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05431270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431270.